Contract development and manufacturing organization, Alliance Contract Pharma (ACP), said one of its clients received FDA approval for the first twice-daily ocular corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.
 
ACP supported the development of this product through a range of phases: formulation development, clinical supply, process validation, FDA inspection and approval, and launch.
 
“The most rewarding aspect of the years of quality-driven hard work, is seeing the success of the client’s FDA approval and the positive impact on the company’s future,” said Benjamin Reed, vice president, manufacturing, Alliance Contract Pharma. “The thoughtful determination through all aspects of the drug life cycle enabled the ease of commercialization.”
 
ACP develops and manufactures a wide range of dosage forms, from discovery to distribution.